Welcome to our dedicated page for Genetron Holdings news (Ticker: GTH), a resource for investors and traders seeking the latest updates and insights on Genetron Holdings stock.
Genetron Holdings Limited (NASDAQ: GTH) is a leading precision oncology platform company based in China. With a focus on cancer molecular profiling, Genetron leverages advanced technologies in molecular biology and data science to revolutionize cancer treatment.
The company's extensive portfolio spans various stages of cancer management, including early screening, diagnosis, treatment recommendations, and continuous monitoring. Some of its flagship services and products include:
- HCCscreen: A proprietary assay for the early detection of liver cancer.
- 8-gene Lung Cancer Assay: An in-vitro diagnostic tool based on semiconductor sequencing for lung cancer detection.
- Genetron 3D Biochip Reading Instrument and Genetron S5 and S2000: Advanced sequencers for gene detection and panel sequencing.
- IDH1/TERT Gene Assays: Diagnostic assays for glioma.
In addition, Genetron has developed a ctDNA Lung Cancer Assay targeting mutations in the epidermal growth factor receptor gene. The company collaborates with global biopharmaceutical firms to offer tailored genomics research and clinical development services.
Recently, Genetron announced a definitive Agreement and Plan of Merger with New Genetron Holding Limited and Genetron New Co Limited. As part of the merger, Genetron will become a wholly-owned subsidiary of the parent company in a transaction valued at approximately US$126.0 million. This merger signifies a pivotal transformation, taking the company private and enhancing its strategic flexibility.
The merger completion, expected in the first quarter of 2024, is subject to customary closing conditions, including shareholder votes and regulatory approvals. Upon completion, Genetron's American Depositary Shares (ADSs) will be delisted from the Nasdaq Global Market, and the company will terminate its ADS program. The company aims to finalise this transition efficiently to focus on its long-term vision and goals.
For the latest updates and detailed information on Genetron Holdings Limited and its innovative contributions to precision oncology, please visit their Investor Relations page.
Genetron Holdings Limited (NASDAQ: GTH) announced that its AYVAKIT® companion diagnostic (CDx) kit has entered the priority review process by China's National Medical Products Administration (NMPA). This CDx kit is the first of its kind to undergo expedited review in China, aimed at enhancing treatment for gastrointestinal stromal tumor (GIST) patients with PDGFRA gene mutations. The kit was developed in collaboration with CStone Pharmaceuticals and offers precise molecular diagnosis, which could lead to better clinical outcomes for patients.
Genetron Holdings Limited (NASDAQ:GTH) announced the receipt of the CE Mark for its 8-gene Lung Cancer Assay, affirming its compliance with European standards. This assay is already approved by China’s NMPA and is designed for swift, independent testing in hospitals. It provides a two-day turnaround from sample to report. Additionally, Genetron shared performance data for its SARS-CoV-2 RNA Test, indicating the best sensitivity among domestic competitors in China. This progress marks significant milestones for Genetron as it aims to enhance global market presence.
Genetron Holdings Limited (NASDAQ: GTH), a leading precision oncology platform in China, has formed a partnership with the World Economic Forum (WEF) to enhance global health access. Through this collaboration, Genetron will contribute its expertise and technologies to the WEF's Health and Healthcare Platform, focusing on initiatives like the project 'Moving Genomics to the Clinic,' aimed at integrating genetic testing in healthcare practices. The partnership aims to drive impactful advancements in the healthcare sector and aligns with Genetron's mission to foster technological innovation and healthcare development in China.
Genetron Holdings Limited (NASDAQ: GTH) announced 16 research results at the 2021 ASCO Annual Meeting, focusing on precision oncology. Collaborating with 16 leading Chinese hospitals, the studies optimized clinical diagnosis methods and explored gene mutation and immunotherapy markers across various cancers. Key findings include a non-invasive method for detecting urothelial tumors, achieving sensitivities of 93% for renal pelvic cancer and 86% for bladder cancer. The research aims to improve the diagnosis and treatment of high-incidence cancers, such as lung and thyroid cancer, enhancing the full-cycle cancer management strategy.
Genetron Holdings Limited (NASDAQ:GTH) announced its preliminary financial results for Q1 2021, reporting total revenue of RMB 92.1 million (US$14.1 million), a 19.8% year-over-year increase. Notably, revenue from LDT services grew by 51.0% to RMB 71.8 million (US$11.0 million), driven by the HCCscreenTM product. Gross margin improved to 59.3%. However, operating loss expanded to RMB 109.0 million (US$16.6 million), and net loss was RMB 115.0 million (US$17.6 million). The company reiterates its 2021 revenue guidance, expecting a 45-47% growth compared to 2020.
Genetron Holdings Limited (Nasdaq: GTH) announced a strategic partnership with JD Health, aiming to innovate full-cycle cancer management solutions. This collaboration focuses on consumer healthcare, liver disease management, and education, with an initial emphasis on liver and lung cancer. Genetron will utilize its HCCscreen™ liquid biopsy and 8-gene lung cancer detection kit. This partnership marks a significant addition to Genetron's commercialization channels and seeks to enhance accessibility to precision oncology products.
Genetron Holdings Limited (NASDAQ:GTH) announced a strategic partnership with Siemens Healthineers at the China Medical Equipment Fair. This collaboration focuses on promoting Genetron's S5 platform and lung cancer 8-gene IVD assay in hospitals, enhancing personalized diagnosis and treatment for NSCLC patients. The partnership aims to standardize cancer molecular testing in China, addressing the significant lung cancer burden, with approximately 787,000 diagnosed and 631,000 deaths annually. The lung cancer 8-gene IVD assay offers rapid molecular typing and targeted therapy guidance.
Genetron Holdings Limited (NASDAQ:GTH), a leading precision oncology platform in China, announced that it will release its unaudited financial results for Q1 2021 on May 24, 2021, prior to the U.S. market opening. A conference call for investors is scheduled for the same day at 8:30 a.m. ET. Genetron specializes in cancer molecular profiling and has developed a comprehensive portfolio for cancer management. The company partners with global biopharmaceutical firms and provides tailored services and products.
Genetron Holdings Limited (Nasdaq: GTH), a precision oncology leader in China, announced participation in three investor conferences in April and May 2021. The management will present at the UBS Virtual Healthcare Summit on April 28-29, followed by the Soochow Securities Innovative Medical Device Corporate Summit in Shanghai on April 30, where Chief Medical Officer Dr. Yun-Fu Hu will speak. The third event is the CICC Healthcare Industry Forum from May 18-19, with CEO Sizhen Wang presenting. Further details are available through their sales representatives.
Genetron Holdings Limited (NASDAQ:GTH) has announced 22 research results at AACR 2021, highlighting advancements in precision oncology. Collaborating with 13 leading Chinese hospitals, the studies utilized innovative technologies, including integrated DNA and RNA sequencing, to enhance cancer diagnostics and treatment. Key findings include a 177% increase in gene fusion detection rates for soft tissue sarcoma and a 99.9% consistency in MSI detection with PCR. The company aims to bridge scientific research and clinical applications to improve cancer care across various types.
FAQ
What is the market cap of Genetron Holdings (GTH)?
What does Genetron Holdings Limited specialize in?
What are some of Genetron's key products?
What recent corporate action has Genetron announced?
What is HCCscreen?
What is the significance of Genetron's merger?
What happens to Genetron's ADSs after the merger?
Who are the major stakeholders involved in the merger?
When is the merger expected to complete?
What services does Genetron offer in genomics research?
Where can I find more information about Genetron's financial filings?
